Jill Carroll
CIK: 0001598542
Jill Carroll's purchase track record
Jill Carroll has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/1/2026 | AVLN | $5.00M | -3.5% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AVLN | ▼ Sell | Other | 1,419,298 | — | 5/1/2026 | View on chart |
| AVLN | ▼ Sell | Other | 489,486 | — | 5/1/2026 | View on chart |
| AVLN | ▲ Buy | Open Market | 277,778 | $5.0M | 5/1/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Avalyn Pharma seen amid biotech pressure after Syndax trial failure
Syndax Pharmaceuticals reported a failed clinical trial, causing its stock to drop sharply. The setback highlights ongoing risks in biotech development and may influence investor sentiment across the sector. Avalyn Pharma, which is trading near its $27.91 support level and has an RSI around 32, could be affected by broader market reactions.
Avalyn Pharma seen amid biotech pressure after Syndax trial failure. Syndax Pharmaceuticals reported a failed clinical trial, causing its stock to drop sharply. The setback highlights ongoing risks in biotech development and may influence investor sentiment across the sector. Avalyn Pharma, which is trading near its $27.91 support level and has an RSI around 32, could be affected by broader market reactions.